Antibody-Drug Conjugates: Carbon-14 Labeling Requirements

The next blockbuster drug revenue streams are likely to come from a class of targeted therapies geared towards the treatment and management of chronic human disease states, especially cancer, and involve the use of antibody-drug conjugates (ADCs).
This article, published in Drug Development and Delivery magazine, May 2013, looks at carbon-14 labelling requirements for these types of drugs and their future development.